Survival for older patients with acute myeloid leukemia: a population-based study
Top Cited Papers
- 6 July 2012
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 97 (12), 1916-1924
- https://doi.org/10.3324/haematol.2012.066100
Abstract
Acute myeloid leukemia is the second most common leukemia among United States adults with a median age of 69 years. We investigated recent clinical practices related to treatments and disease outcomes in older patients with acute myeloid leukemia in the United States. In this retrospective cohort study, we used Surveillance, Epidemiology, and End Results program data from 2000 through 2007 linked to Medicare enrollment and utilization data in the United States. Among 5,480 patients with acute myeloid leukemia (median age 78 years, range 65-93), 38.6% received leukemia therapy within three months of diagnosis (treated group). Practice changed with 16.3% of treated patients receiving hypomethylating agents after 2004 when those agents became available. Median survival was two months in the untreated group versus six months in the treated group (P<0.01) with the biggest improvements seen in those aged 65-69 years (10 months vs. 4 months; P<0.01) and 70-74 years (8 months vs. 3 months; P<0.01). In 46 patients receiving allogeneic hematopoietic cell transplantation (0.8%), the median survival from diagnosis was 22 months. Therapy for leukemia improves overall survival in older acute myeloid leukemia patients. Based on their comorbidities, most patients up to 80 years of age should be considered for treatment. New therapies including hypomethylating agents and allogeneic hematopoietic cell transplantation are promising and must be compared with other chemotherapy regimens.This publication has 41 references indexed in Scilit:
- Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First RemissionTransplantation and Cellular Therapy, 2011
- Ascertainment of Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaBlood, 2010
- Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemiaBlood, 2010
- Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic SyndromeJournal of Clinical Oncology, 2010
- Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significanceBlood, 2009
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia RegistryBlood, 2009
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsThe New England Journal of Medicine, 1999